MicroRNAs affecting the susceptibility of melanoma cells to CD8+ T cell-mediated cytolysis

被引:2
|
作者
Pane, Antonino A. A. [1 ,2 ,8 ,9 ]
Kordass, Theresa [1 ,2 ]
Hotz-Wagenblatt, Agnes [3 ]
Dickes, Elke [1 ]
Kopp-Schneider, Annette [4 ]
Will, Rainer [5 ]
Seliger, Barbara [6 ]
Osen, Wolfram [1 ]
Eichmueller, Stefan B. B. [1 ,7 ]
机构
[1] German Canc Res Ctr, Res Grp GMP & T Cell Therapy, Heidelberg, Germany
[2] Heidelberg Univ, Fac Biosci, Heidelberg, Germany
[3] German Canc Res Ctr, Om IT & Data Management Core Facil, Heidelberg, Germany
[4] German Canc Res Ctr, Dept Biostat, Heidelberg, Germany
[5] German Canc Res Ctr, Core Facil Cellular Tools, Heidelberg, Germany
[6] Martin Luther Univ Halle Wittenberg, Inst Med Immunol, Halle, Germany
[7] German Canc Res Ctr, Res Grp GMP& T Cell Therapy, Heidelberg, Germany
[8] Immatics Biotechnol GmbH, Tubingen, Germany
[9] Univ Clin Heidelberg, Sect Multiple Myeloma Internal Med 5, Heidelberg, Germany
来源
CLINICAL AND TRANSLATIONAL MEDICINE | 2023年 / 13卷 / 02期
关键词
cytotoxic T lymphocyte (CTL); melanoma; miRNA; Ndufa1; Psmc3; screening; DOWN-REGULATION; CANCER-CELLS; RESISTANCE; PROGRESSION; PROTEASOME; PHENOTYPE; BLOCKADE; THERAPY; PATHWAY; GENES;
D O I
10.1002/ctm2.1186
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThe regulatory functions of microRNAs (miRNAs) in anti-tumour immunity have been mainly described in immune effector cells. Since little is known about miRNA effects on the susceptibility of target cells during T cell-target cell interaction, this study focused on the identification of miRNAs expressed in tumour cells controlling their susceptibility to CD8(+) T cell-mediated cytotoxicity. MethodsLuciferase expressing B16F10 melanoma (B16F10 Luci(+)) cells transfected with individual miRNAs covering a comprehensive murine miRNA library were screened for their susceptibility to lysis by an established cytotoxic T lymphocyte (CTL) line (5a, clone N beta) specific for the melanoma-associated antigen tyrosinase-related protein 2. miRNAs with the most pronounced effects on T cell-mediated lysis were validated and stably expressed in B16F10 cells. In silico analyses identified common targets of miRNA sets determined by the screen, which were further confirmed by small interfering RNA (siRNA)-mediated silencing experiments modulating immune surveillance. The Ingenuity Pathway Analysis (IPA) software and RNA sequencing (RNA-seq) data from miRNA-overexpressing cell lines were applied to investigate the underlying mechanisms. The Cancer Genome Atlas (TCGA)-derived miRNA sequencing data were used to assess the correlation of miRNA expression with melanoma patients' survival. ResultsThe miRNA screen resulted in the selection of seven miRNAs enhancing CTL-mediated melanoma cell killing in vitro. Upon stable overexpression of selected miRNAs, hsa-miR-320a-3p, mmu-miR-7037-5p and mmu-miR-666-3p were determined as most effective in enhancing susceptibility to CTL lysis. In silico analyses and subsequent siRNA-mediated silencing experiments identified Psmc3 and Ndufa1 as common miRNA targets possibly involved in the functional effects observed. The analyses of RNA-seq data with IPA showed pathways, networks, biological functions and key molecules potentially involved in the miRNA-mediated functional effects. Finally, based on TCGA data analysis, a positive correlation of the conserved miRNAs among the panel of the seven identified miRNAs with overall survival of melanoma patients was determined. ConclusionsFor the first time, this study uncovered miRNA species that affect the susceptibility of melanoma cells to T cell-mediated killing. These miRNAs might represent attractive candidates for novel therapy approaches against melanoma and other tumour entities.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] CD8+ T cell-mediated injury in vivo progresses in the absence of effector T cells
    Small, BA
    Dressel, SA
    Lawrence, CW
    Drake, DR
    Stoler, MH
    Enelow, RI
    Braciale, TJ
    JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (12): : 1835 - 1846
  • [2] Regulatory CD4+ T cells are crucial for preventing CD8+ T cell-mediated autoimmunity
    Poitrasson-Riviere, Maud
    Bienvenu, Boris
    Le Campion, Armelle
    Becourt, Chantal
    Martin, Bruno
    Lucas, Bruno
    JOURNAL OF IMMUNOLOGY, 2008, 180 (11): : 7294 - 7304
  • [3] Immune regulation in CD8+ T cell-mediated pulmonary disease
    Tosiek, Milena J.
    Gruber, Achim D.
    Gereke, Marcus
    Bruder, Dunja
    CYTOKINE, 2009, 48 (1-2) : 104 - 104
  • [4] Cytotoxicity is mandatory for CD8+ T cell-mediated contact hypersensitivity
    Kehren, J
    Desvignes, C
    Krasteva, M
    Ducluzeau, MT
    Assossou, O
    Horand, F
    Hahne, M
    Kägi, D
    Kaiserlian, D
    Nicolas, JF
    JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (05): : 779 - 786
  • [5] Type 1 narcolepsy: a CD8+ T cell-mediated disease?
    Degn, Matilda
    Kornum, Birgitte Rahbek
    NEUROIMMUNOMODULATION IN HEALTH AND DISEASE, 2015, 1351 : 80 - 88
  • [6] Inhibition of the CD8+ T cell-mediated cytotoxicity reaction by hypericin:: potential for treatment of T cell-mediated diseases
    Lavie, G
    Meruelo, D
    Aroyo, K
    Mandel, M
    INTERNATIONAL IMMUNOLOGY, 2000, 12 (04) : 479 - 486
  • [7] CD8+ T cell-mediated airway hyperresponsiveness and inflammation is dependent on CD4+IL-4+ T cells
    Koya, Toshiyuki
    Miyahara, Nobuaki
    Takeda, Katsuyuki
    Matsubara, Shigeki
    Matsuda, Hiroyuki
    Swasey, Christina
    Balhorn, Annette
    Dakhama, Azzeddine
    Gelfand, Erwin W.
    JOURNAL OF IMMUNOLOGY, 2007, 179 (05): : 2787 - 2796
  • [8] Gads Regulates the Expansion Phase of CD8+ T Cell-Mediated Immunity
    Zhang, Elizabeth Yan
    Parker, Brooks L.
    Yankee, Thomas M.
    JOURNAL OF IMMUNOLOGY, 2011, 186 (08): : 4579 - 4589
  • [9] No intrinsic deficiencies in CD8+ T cell-mediated antitumor immunity with aging
    Norian, LA
    Allen, PM
    JOURNAL OF IMMUNOLOGY, 2004, 173 (02): : 835 - 844
  • [10] Lactobacillus casei reduces CD8+ T cell-mediated skin inflammation
    Chapat, L
    Chemin, K
    Dubois, B
    Bourdet-Sicard, R
    Kaiserlian, D
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (09) : 2520 - 2528